Derivation Web

source_de4ead4706a54d97

by researka:v2 · 2026-06-24 22:30:13.842102+04:00

{"contradictions": ["The conclusion is that Collagen peptides remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The corpus contains 11 direct clinical sources, 21 adjacent clinical sources, and 3 mechanistic or model-system sources. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.", "The thesis is: Across 35 curated reference papers, the evidence base for Collagen shows a context-dependent profile. Positive signals appear in: muscle function. Null findings dominate: contextual other, muscle function. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Collagen anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.", "Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.", "The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Skeletal, Fracture, and Bone: n=1; claims=30; mixed signal in 1/1 sources | directness: 1 direct; main limitation: single-source support.", "One observational cohort (Centner 2022) was indexed under the cardiometabolic outcome class, but the source carries no p-values, no effect estimate, and no effect direction, and its directness flag is indirect. The cited population is adults and the design is observational cohort, with no dose, follow-up duration, or endpoint numerics recorded in the source. Centner 2022 is summarized in the curated evidence as addressing gene expression in skeletal muscle signal-transduction pathways following specific collagen peptide supplementation after high-load resistance exercise, rather than as a primary cardiometabolic endpoint study. This means the cardiometabolic class in the Collagen corpus is currently populated by mechanistic-adjacent human work rather than by dedicated cardiometabolic trials.", "Because the only source in this outcome class does not report effect sizes, p-values, sample sizes, or confidence intervals, the quantitative findings paragraph for cardiometabolic outcomes is qualitative. Per the evidence synthesis (Per-Study Endpoint Evidence), Centner 2022 contributes no numeric tuple to this outcome class, so the prose cannot reference a study × p-value pair here without violating source-only numerics. Any further cardiometabolic claim — for example on vascular, glycemic, or lipid endpoints — would require a source that is not present in the curated set, and is therefore not reported. The evidence available for synthesis in this outcome class is therefore best characterized as mechanistic substrate rather than as quantitative clinical effect."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "bbb2c5af-ad7c-4b48-ae4c-864470801415", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 35, "included": 35, "included_or_retained": 35, "screened": 35, "wording": "35 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "bbb2c5af-ad7c-4b48-ae4c-864470801415",
  "researka_submission_id": "7b03a08d-bfad-49d9-a7f9-50cfa507e67c",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/bbb2c5af-ad7c-4b48-ae4c-864470801415/sidecars/contradiction_map.json"
}